Brion is currently Chief Business Officer at Luminopia Inc, a prescription digital therapeutics startup pioneering a new class of treatments for neuro-visual disorders. Luminopia’s first product is FDA-approved software that allows pediatric amblyopia (lazy eye) patients to watch TV or movies for an hour a day inside a VR headset as treatment, rather than wearing an eye patch for 2-12 hours a day.
Prior to Luminopia, he was Chief Commercial Officer at Clearside Biomedical where he built the commercial infrastructure to support the launch of XIPERE™, before ultimately out-licensing the asset to Bausch Health in early 2020. Prior to Clearside, Brion led cross-functional launch teams at two other small biotech companies, XOMA and Dynavax, after spending 10 years at Genentech where he launched Lucentis®, a blockbuster treatment for macular degeneration, and Erivedge®, a treatment for a rare form of skin cancer.
Brion holds a BS in Optics from the University of Rochester and an MBA from the Tuck School of Business at Dartmouth College.
Prior to Luminopia, he was Chief Commercial Officer at Clearside Biomedical where he built the commercial infrastructure to support the launch of XIPERE™, before ultimately out-licensing the asset to Bausch Health in early 2020. Prior to Clearside, Brion led cross-functional launch teams at two other small biotech companies, XOMA and Dynavax, after spending 10 years at Genentech where he launched Lucentis®, a blockbuster treatment for macular degeneration, and Erivedge®, a treatment for a rare form of skin cancer.
Brion holds a BS in Optics from the University of Rochester and an MBA from the Tuck School of Business at Dartmouth College.
Speaking In
1:00 PM - 2:00 PM
Monday, June 5
